组蛋白去乙酰化酶9表达与恶性肿瘤预后相关性的Meta分析

The prognostic value of HDAC9 expression in malignant tumor:a Meta analysis

目的分析组蛋白去乙酰化酶9(HDAC9)表达水平与恶性肿瘤预后的相关性。方法计算机检索PubMed、EMbase、The Cochrane Library、中国期刊全文数据库和万方数据库,搜集HDAC9表达对恶性肿瘤预后相关性的病例对照研究,检索时限均为建库至2019年3月。筛选文献并提取数据,使用RevMan 5.3软件进行Meta分析。结果共纳入8篇病例对照研究,Meta分析结果显示,HDAC9高表达与性别(OR=0.87,95%CI=0.22~3.40,P=0.84)、TNM分期(OR=0.55,95%CI=0.20~1.52,P=0.25)、无进展生存期(HR=1.10,95%CI=0.97~1.26,P=0.14)无关,但与淋巴结转移(OR=2.25,95%CI=1.18~4.29,P=0.01),总生存期(HR=2.51,95%CI=1.11~5.66,P=0.03)和无事件生存期(HR=10.61,95%CI=1.26~86.90,P=0.03)显著相关。结论HDAC9的高表达是恶性肿瘤病人不良预后的危险因素。

Objective To evaluate the prognostic value of histone deacetylase 9(HDAC9)expression in malignant tumor.Methods Databases including PubMed,EMbase,The Cochrane Library,CNKI and WanFang Data were searched to collect case-control studies about the prognostic value of HDAC9 expression in malignant tumor from inception to Jan 2019.Literatures were screened and data was extracted.Then meta-analysis was performed by using RevMan 5.3 software.Results Finally,a total of 8 case-control studies were included.The results of meta-analysis showed that the high expression of HDAC9 was not associated with gender(OR=0.87,95%CI=0.22~3.40,P=0.84),TNM staging(OR=0.55,95%CI=0.20~1.52,P=0.25)and progression-free survival(HR=1.10,95%CI=0.97~1.26,P=0.14).But the high expression of HDAC9 was significantly associated with lymph node metastasis(OR=2.25,95%CI=1.18~4.29,P=0.01),overall survival(HR=2.51,95%CI=1.11~5.66,P=0.03)and event-free survival(HR=10.61,95%CI=1.26~86.90,P=0.03).Conclusion HDAC9 high expression is a risk factor for poor prognosis in cancer patients and may be used as a predictive maker for poor prognosis in malignant tumor.